Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

2.
3.

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.

Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.

Oncol Rep. 2014 Aug;32(2):553-8. doi: 10.3892/or.2014.3268. Epub 2014 Jun 13.

PMID:
24927217
4.

Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.

Takai M, Nakagawa T, Tanabe A, Terai Y, Ohmichi M, Asahi M.

Cancer Biol Ther. 2015;16(2):325-35. doi: 10.1080/15384047.2014.1002362.

5.

Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.

Kim SI, Lee JW, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Seo JS.

Gynecol Oncol. 2018 Feb;148(2):375-382. doi: 10.1016/j.ygyno.2017.12.005. Epub 2017 Dec 9.

PMID:
29233531
6.

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B.

Oncotarget. 2016 Jun 14;7(24):35753-35767. doi: 10.18632/oncotarget.7099.

7.

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.

Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D, Xiong J, Darr DB, Pardo-Manuel de Villena F, Kim WY, Magnuson T.

Nat Commun. 2015 Jan 27;6:6118. doi: 10.1038/ncomms7118.

8.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.

Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.

Mod Pathol. 2014 Jul;27(7):983-90. doi: 10.1038/modpathol.2013.216. Epub 2013 Dec 13.

9.

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.

Kuroda T, Ogiwara H, Sasaki M, Takahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T.

Gynecol Oncol. 2019 Dec;155(3):489-498. doi: 10.1016/j.ygyno.2019.10.002. Epub 2019 Oct 8.

PMID:
31604667
10.

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.

Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T.

Br J Cancer. 2017 Aug 22;117(5):717-724. doi: 10.1038/bjc.2017.228. Epub 2017 Jul 20.

11.

Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.

Shibuya Y, Tokunaga H, Saito S, Shimokawa K, Katsuoka F, Bin L, Kojima K, Nagasaki M, Yamamoto M, Yaegashi N, Yasuda J.

Genes Chromosomes Cancer. 2018 Feb;57(2):51-60. doi: 10.1002/gcc.22507. Epub 2017 Oct 30.

PMID:
29044863
12.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
13.

Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.

Huang HN, Huang WC, Lin CH, Chiang YC, Huang HY, Kuo KT.

Hum Pathol. 2014 Nov;45(11):2318-25. doi: 10.1016/j.humpath.2014.07.020. Epub 2014 Aug 16.

PMID:
25281027
14.

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.

15.

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N.

Science. 2010 Oct 8;330(6001):228-31. doi: 10.1126/science.1196333. Epub 2010 Sep 8.

16.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 Aug;37(33):4611-4625. doi: 10.1038/s41388-018-0300-6. Epub 2018 May 15.

17.

Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.

Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K.

Int J Cancer. 2017 Nov 1;141(9):1856-1866. doi: 10.1002/ijc.30847. Epub 2017 Jul 24.

18.

Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.

Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R.

Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4. Review.

PMID:
28189457
20.

Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.

Kawata T, Tada K, Kobayashi M, Sakamoto T, Takiuchi Y, Iwai F, Sakurada M, Hishizawa M, Shirakawa K, Shindo K, Sato H, Takaori-Kondo A.

Cancer Sci. 2018 Jan;109(1):103-111. doi: 10.1111/cas.13431. Epub 2017 Nov 22.

Supplemental Content

Support Center